Chromium

The dosage of Chromic must be individualized based on the patient's metabolic requirements and clinical status. For stable adults receiving Total Parenteral Nutrition (TPN), the standard recommended dose of trivalent chromium is 10 to 15 mcg per day.

In patients with active chromium deficiency (characterized by glucose intolerance and high insulin requirements), a healthcare provider may temporarily increase the dose to 20 mcg per day until the metabolic state stabilizes. It is critical to note that these doses are for intravenous administration; oral doses of chromium (often found in over-the-counter supplements) are significantly higher (200-1000 mcg) due to poor intestinal absorption.

Chromic is approved for use in pediatric patients receiving TPN, but the dosage is strictly weight-based to prevent toxicity.

• Infants and Children: The recommended dose is 0.14 to 0.2 mcg/kg per day.
• Preterm Neonates: Special care must be taken as renal function is immature. Dosing usually starts at the lower end of the pediatric range and is closely monitored by a neonatologist.

> Warning: Excessive administration to infants can lead to accumulation and potential toxicity. Always follow the specific calculations provided by the neonatal intensive care unit (NICU) staff.

Renal Impairment

Chromic is primarily excreted by the kidneys. In patients with moderate to severe renal impairment (Stage 3-5 Chronic Kidney Disease), the dose must be significantly reduced or withheld. Healthcare providers typically monitor serum chromium levels and renal function (creatinine clearance) to avoid toxic accumulation. Accumulation in renal failure can lead to nephrotoxicity, creating a dangerous feedback loop.

Hepatic Impairment

While chromium is stored in the liver, it is not metabolized there. No specific dose adjustments are generally required for patients with isolated hepatic impairment, though global nutritional status should be monitored.

Elderly Patients

Geriatric patients often have a natural decline in glomerular filtration rate (GFR). Therefore, dosing should be conservative, starting at the lower end of the adult range (10 mcg/day), with frequent monitoring of kidney function.

Chromic Sulfate is not intended for direct injection. It must be prepared and administered as follows:

1. 1Dilution: The concentrated Chromic solution must be added to a large volume of TPN solution (usually 1 to 3 liters) under aseptic conditions in a pharmacy.
2. 2Administration: The TPN solution containing Chromic is administered via a central venous catheter or, in some cases, a peripheral IV line, using an infusion pump to ensure a constant rate.
3. 3Storage: Vials should be stored at room temperature (20°C to 25°C). Once added to a TPN bag, the solution is typically stable for 24 hours under refrigeration.

In the context of TPN, a 'missed dose' usually means the infusion was interrupted. If the TPN pump stops or the bag runs out, contact your healthcare provider immediately. Do not attempt to 'double up' the infusion rate to catch up, as this can cause fluctuations in blood sugar levels and potential electrolyte imbalances.

Chromic overdose is rare but serious. Signs of acute toxicity include:

• Severe nausea and vomiting
• Gastrointestinal hemorrhage
• Acute renal failure (decreased urine output)
• Liver damage (yellowing of the skin or eyes)
• Convulsions or coma in extreme cases

In the event of a suspected overdose, the infusion must be stopped immediately. Treatment is supportive and may involve hemodialysis to remove excess chromium from the blood. If you suspect an overdose, call 911 or your local emergency services immediately.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or the rate of your TPN infusion without medical guidance.

Because Chromic is an essential trace element administered in microgram quantities, side effects are rare when dosed correctly. However, in the context of TPN administration, some patients may experience:

• Injection Site Reactions: Redness, swelling, or 'phlebitis' (inflammation of the vein) at the site of the IV insertion. This often feels like a warm, tender area along the vein.
• Changes in Blood Glucose: As Chromic improves insulin sensitivity, some patients may experience mild hypoglycemia (low blood sugar) if their insulin dose is not adjusted accordingly. Symptoms include shakiness, sweating, and lightheadedness.

• Gastrointestinal Distress: Mild nausea or abdominal cramping, although this is more common with oral chromium than IV Chromic Sulfate.
• Skin Rash: Some patients may develop a mild, itchy rash (urticaria) if they have a borderline sensitivity to chromium salts.
• Headache: Occasional reports of mild headaches have been noted during the initiation of trace element supplementation.

• Chromium Toxicity: This typically only occurs in patients with severe kidney disease who cannot excrete the mineral. Symptoms include metallic taste, dermatitis, and changes in mental status.
• Anaphylactoid Reactions: While extremely rare, some individuals may have a severe allergic reaction to the sulfate component or the chromium itself, resulting in difficulty breathing or facial swelling.

> Warning: Stop the infusion and call your doctor immediately if you experience any of the following:

1. 1Acute Nephrotoxicity: Signs include a sudden decrease in urine output, swelling in the legs or ankles, and fatigue. This suggests the chromium may be damaging the kidneys.
2. 2Hepatotoxicity: Signs include yellowing of the eyes or skin (jaundice), dark urine, and right-sided abdominal pain. Trivalent chromium can accumulate in the liver if over-administered.
3. 3Severe Hypoglycemia: Confusion, seizures, or loss of consciousness. Because Chromic makes insulin work better, it can cause blood sugar to drop dangerously low if not monitored.
4. 4Peripheral Neuropathy: While chromium treats neuropathy caused by deficiency, excessive levels can paradoxically cause numbness, tingling, or 'pins and needles' in the hands and feet.

Prolonged use of Chromic in TPN requires careful monitoring for 'Trace Element Overload.' Over several years, chromium can deposit in the bones and soft tissues. Long-term effects may include:

• Reduced Bone Mineral Density: Some studies suggest that excessive trace element accumulation can interfere with normal bone remodeling.
• Cognitive Changes: There are theoretical concerns regarding long-term accumulation in the brain, though this is not well-documented in humans at standard TPN doses.
• Dermatological Sensitization: Long-term exposure to chromium salts can lead to the development of a permanent chromium allergy, manifesting as chronic eczema or contact dermatitis.

No FDA black box warnings currently exist for Chromic Sulfate. However, the FDA does require a general warning on all small-volume parenterals regarding Aluminum Toxicity. Many vials of Chromic Sulfate contain trace amounts of aluminum as a contaminant from the glass or manufacturing process. In patients with impaired kidney function or in premature infants, this aluminum can accumulate to toxic levels, leading to 'Aluminum Bone Disease' and encephalopathy. Healthcare providers must calculate the total daily aluminum intake from all TPN components.

Report any unusual symptoms, especially changes in mood, urination, or skin condition, to your healthcare provider immediately.

Chromic is a potent trace mineral that must only be administered under the supervision of a healthcare professional experienced in parenteral nutrition. The most critical safety factor is the balance between preventing deficiency and avoiding toxicity. Patients must undergo regular blood testing to ensure that the levels of chromium and other electrolytes remain within a safe therapeutic window.

As of 2026, there are no FDA black box warnings for Chromic (Chromic Sulfate). However, it is subject to the standard 'Parenteral Aluminum Warning' for all IV nutritional products. This warning highlights that the product may contain aluminum that could be toxic to premature neonates and patients with renal impairment.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known allergy to other metals (like nickel or cobalt) may have a higher risk of cross-sensitivity to chromium. If you have ever had a reaction to jewelry or metal fasteners, inform your doctor.
• Nephrotoxicity: Chromic is cleared by the kidneys. If you have pre-existing kidney disease, the risk of the drug accumulating to toxic levels is significantly increased. Your doctor will perform 'Creatinine Clearance' tests before and during treatment.
• Hepatotoxicity: While rare, trivalent chromium can cause liver stress if administered in excess. Patients with underlying liver cirrhosis or hepatitis should be monitored for changes in liver enzymes (ALT/AST).
• Diabetes Management: Because Chromic increases insulin sensitivity, patients with diabetes may need to have their insulin or oral hypoglycemic doses lowered. Failure to adjust these medications can lead to severe, life-threatening hypoglycemia.

If you are receiving Chromic as part of TPN, your healthcare team will perform the following tests regularly:

1. 1Serum Glucose: Often checked multiple times daily when starting TPN to ensure stability.
2. 2Renal Function Tests: Monthly or weekly checks of BUN (Blood Urea Nitrogen) and Creatinine.
3. 3Serum Chromium Levels: While not a routine daily test, these are checked periodically (e.g., every 3-6 months) for patients on long-term parenteral nutrition.
4. 4Liver Function Tests (LFTs): To ensure the liver is processing the TPN components correctly.

Chromic itself does not typically cause sedation or cognitive impairment. However, if Chromic causes your blood sugar to drop (hypoglycemia), you may experience dizziness or blurred vision. Do not drive or operate heavy machinery until you are certain your blood sugar is stable.

Alcohol can interfere with glucose metabolism and may worsen the symptoms of chromium deficiency or mask the signs of chromium toxicity. Furthermore, chronic alcohol use can damage the kidneys, making it harder for your body to clear Chromic. It is generally advised to avoid alcohol while on TPN.

Chromic should not be stopped abruptly if you are still dependent on TPN for your nutrition, as this can lead to a return of glucose intolerance. If you are transitioning to oral feedings, your doctor will gradually 'taper' the TPN and monitor your ability to maintain blood sugar levels through diet alone.

> Important: Discuss all your medical conditions, especially any history of kidney disease or metal allergies, with your healthcare provider before starting Chromic.

There are no medications that are strictly contraindicated with Chromic Sulfate in a way that prohibits use entirely; however, its use is contraindicated in patients with known hypersensitivity to chromium.

• Insulin and Sulfonylureas: Chromic significantly enhances the pharmacological effect of insulin and insulin secretagogues (like glipizide or glyburide). The clinical consequence is a high risk of severe hypoglycemia. Management: Healthcare providers must monitor blood glucose closely and proactively reduce the dose of diabetes medications when starting Chromic.
• Corticosteroids (e.g., Prednisone): Steroids typically cause hyperglycemia (high blood sugar) and can antagonize the glucose-lowering effects of chromium. Management: Patients on both may require higher doses of insulin despite the chromium supplementation.

• NSAIDs (e.g., Ibuprofen, Naproxen): Non-steroidal anti-inflammatory drugs can reduce renal blood flow and impair the excretion of chromium, potentially leading to higher serum levels. Management: Use NSAIDs with caution in patients with borderline renal function receiving Chromic.
• Levothyroxine: Some studies suggest that chromium may interfere with the absorption of thyroid hormones if taken orally. While this is less of a concern with IV Chromic, monitoring of TSH levels is recommended for patients on thyroid replacement therapy.

• Vitamin C (Ascorbic Acid): Enhances the absorption and cellular uptake of chromium. While usually beneficial, excessive Vitamin C intake could theoretically increase the risk of chromium accumulation.
• Phytic Acid and Antacids: These substances (found in high-fiber foods and over-the-counter medications) can bind to chromium in the gut and prevent absorption. This is primarily a concern for patients transitioning from IV Chromic to oral chromium supplements.

• St. John's Wort: May affect general metabolic pathways, though no specific interaction with chromium is documented.
• Zinc and Iron Supplements: High doses of other trace minerals can compete for transport proteins (like transferrin). If you are taking high-dose iron or zinc, your doctor may need to adjust the ratios in your TPN bag to ensure all minerals are absorbed effectively.

• Glycated Hemoglobin (A1c): By improving long-term glucose control, Chromic will naturally lower A1c levels. This is a therapeutic effect, not a 'false' result, but it must be interpreted in the context of the new supplementation.
• Serum Iron/TIBC: Because chromium binds to transferrin, it can theoretically interfere with tests for iron-binding capacity, though this is rarely clinically significant at standard doses.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those bought without a prescription.

Chromic (Chromic Sulfate) must NEVER be used in the following circumstances:

1. 1Known Hypersensitivity: Patients who have had an anaphylactic reaction or severe systemic dermatitis in response to chromium or any component of the injection (such as sulfates) must not receive this medication. The mechanism is an IgE-mediated or delayed-type T-cell hypersensitivity.
2. 2Severe Renal Failure (Anuric): In patients who are not producing urine and are not on dialysis, Chromic is absolutely contraindicated. Because the kidneys are the only significant exit route for chromium, administration would lead to rapid, life-threatening systemic toxicity.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Moderate Renal Impairment: The risk of accumulation must be weighed against the risk of chromium deficiency. Doses are typically reduced by 50-75%.
• Active Peptic Ulcer Disease: While primarily a concern for oral chromium (which is acidic), systemic chromium can occasionally aggravate GI sensitivity.
• Metal Sensitivity: Patients with 'Contact Dermatitis' to chromium (common in construction workers exposed to cement) may be able to tolerate IV Chromic, but they must be monitored for a 'systemic flare' of their skin condition.

There is evidence of cross-sensitivity between Chromium, Nickel, and Cobalt. Patients who have 'jewelry allergies' or reactions to stainless steel should be treated with caution. If a patient develops an unexplained rash while on TPN, Chromic should be suspected as a potential allergen.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of kidney disease or skin allergies, before prescribing Chromic.

Chromic is classified as FDA Pregnancy Category C. This means that adequate animal reproduction studies have not been conducted, and it is not known whether Chromic can cause fetal harm when administered to a pregnant woman.

• Risk-Benefit: Trivalent chromium is an essential nutrient, and deficiency during pregnancy can lead to gestational diabetes and poor fetal growth. Therefore, if a pregnant woman requires TPN, Chromic is typically included at standard doses.
• Monitoring: Close monitoring of blood glucose is required, as insulin requirements change rapidly during the second and third trimesters.

Chromium is naturally present in human breast milk. When administered at the recommended TPN doses, it is unlikely that Chromic Sulfate will significantly increase the concentration of chromium in milk beyond physiological levels. No adverse effects have been reported in nursing infants whose mothers were receiving TPN. However, caution is advised, and the infant should be monitored for normal growth and development.

Chromic is safe and effective for use in children, provided the dose is calculated based on weight (0.14 to 0.2 mcg/kg/day).

• Premature Infants: This population is at the highest risk for Aluminum Toxicity from TPN additives. Their kidneys are not fully developed, making them susceptible to the accumulation of both chromium and aluminum contaminants. Use in neonates must be managed by a specialized neonatal pharmacist.

Clinical studies of Chromic did not include sufficient numbers of subjects aged 65 and over to determine if they respond differently than younger subjects. However, the primary concern in the elderly is the age-related decline in renal function. Because Chromic is renally excreted, elderly patients should have their GFR (Glomerular Filtration Rate) monitored frequently. If GFR falls below 60 mL/min, a dose reduction should be considered.

In patients with impaired kidney function, the clearance of Chromic is significantly reduced.

• Mild-to-Moderate (GFR 30-60): Reduce dose by 50%.
• Severe (GFR <30): Withhold Chromic or administer only once weekly with serum level monitoring.
• Dialysis: Chromium is partially removed by hemodialysis. Patients on dialysis may still require small amounts of chromium, but levels must be checked to prevent toxicity.

No specific dose adjustments are required for patients with liver disease, but since these patients often have complex nutritional needs and are prone to 'TPN-associated cholestasis,' liver enzymes should be monitored regularly.

> Important: Special populations require individualized medical assessment and frequent laboratory monitoring.

Chromic (trivalent chromium) is an essential mineral that acts as a physiological enhancer of insulin activity. The specific molecular mechanism involves the formation of a complex with a peptide called chromodulin. When insulin binds to the extracellular alpha-subunit of the insulin receptor, it triggers the autophosphorylation of the intracellular beta-subunit.

Chromodulin, in its chromium-saturated state, binds to this activated receptor, stabilizing its 'active' conformation and increasing the activity of the tyrosine kinase enzyme by up to 8-fold. This results in an amplified signal for the translocation of glucose transporter proteins (GLUT4) from the cytoplasm to the cell membrane, facilitating the entry of glucose into the cell. Additionally, Chromic inhibits the enzyme phosphotyrosine phosphatase, which normally turns off the insulin receptor, thereby prolonging the insulin signal.

The pharmacodynamic effect of Chromic is measured by its ability to lower blood glucose and reduce the amount of exogenous insulin required by a patient. The onset of action is not immediate; in patients with a deficiency, it may take 3 to 7 days of continuous supplementation to see a stabilization in glucose levels. The duration of effect is long, as chromium is stored in tissues and slowly released.

| Parameter | Value |

|---|---|

| Bioavailability | 100% (Intravenous) |

| Protein Binding | 80-90% (Transferrin and Albumin) |

| Half-life | Biphasic: 8 hours (initial) / 15-30 days (terminal) |

| Tmax | Immediate (IV administration) |

| Metabolism | None (Elemental) |

| Excretion | Renal (80-95%), Fecal (trace) |

• Molecular Formula: Cr2(SO4)3 (Chromic Sulfate)
• Molecular Weight: 392.18 g/mol
• Solubility: Highly soluble in water; insoluble in alcohol.
• Description: Chromic Sulfate typically appears as a violet or green crystalline solid in its anhydrous or hydrated forms. In medical preparations, it is a clear, odorless liquid.

Chromic is classified as a Trace Element and a Nutritional Supplement. Within the EPC system, it is listed as a Methylating Agent, reflecting its involvement in complex biochemical methyl-transfer reactions, though this is not its primary clinical identity. It is related to other TPN additives like Zinc Sulfate, Cupric Sulfate, and Manganese Selenite.